CDK18 is amplified in about 20% of invasive breast carcinomas, 12% of metastatic prostate cancers, and 5% serous ovarian cancers (cBioPortal), suggesting its role as a cancer driver. Here, CDK18 is linked to ovarian serous adenocarcinoma.